The promotion and reimbursement practices for the medtech company’s implantable CPAP alternative are under scrutiny.

During its fourth-quarter earnings call this week, Inspire Medical disclosed that it has become the subject of a civil probe ...

CEO Tim Herbert told investors the company received a civil investigative demand from the Department of Justice in January ...

Inspire Medical shares dipped — but have since mostly recovered — following news of a government investigation following Q4 ...

Inspire Medical Systems, Inc. INSP delivered an earnings per share (EPS) of $1.15 in fourth-quarter 2024, up 134.7% from the ...

In a highly anticipated conference call, Inspire Medical Systems reported an impressive fourth quarter and full year 2024 ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Inspire Medical Systems (INSP – Research ...

Leerink Partners made a slight adjustment to the price target of Inspire Medical Systems (NYSE:INSP), raising it from $193.00 to $194.00, while keeping a Market Perform rating on the stock. According ...

Inspire Medical Systems, Inc. ( NYSE: INSP) Q4 2024 Earnings Conference Call February 10, 2025 5:00 PM ET Ezgi Yagci - Vice President of Investor Relations Tim Herbert - President & Chief Executive ...

CEO Tim Herbert highlighted milestones in 2024, including surpassing 90,000 patients treated with Inspire therapy, FDA approval of the Inspire V neurostimulator, and achieving full-body MRI ...

Inspire Medical Systems ( INSP -0.64%), known for its innovative devices that use neurostimulation to treat sleep apnea, ...

Inspire Medical Systems said it is cooperating with U.S. Justice Department probe of allegations into allegations of false claims related to its Inspire system apnea implant. Shares fall 5.5% to $171 ...